OpGen and Femasys: Pre-Market Action Unveiled
- September 29th, 2023
- 515 views
Shares of OpGen, Inc. (Nasdaq: OPGN) surged by more than 100% in pre-market trading following a regulatory filing with the Securities and Exchange Commission (SEC), requesting the SEC's consent to withdraw the company's Registration Statement on Form S-1, along with all related amendments and exhibits. It's important to note that the Registration Statement had not been declared effective, and no securities covered by it had been issued or sold.
$OPGN was trading at $0.48 pre-market, marking a substantial gain of $0.28 (+139.65%).
In other news, Femasys Inc. (Nasdaq: FEMY), a notable healthcare company, received a positive review from HC Wainwright & Co., which upheld its "Buy" rating on the stock and increased the price target from $5 to $13.
Considering Thursday's closing price of $1.52 for $FEMY, the revised price target suggests a substantial potential upside of $11.48 per share or approximately 753.68%, based on the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login